About Deerfield

Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy—all toward the end goal of cures for disease, improved quality of life, and reduced cost of care.

Read More

Supporting companies across the healthcare ecosystem with flexible funding models…

Read More

Delivering market research to the Deerfield team, its portfolio companies and other partners.

Read More ---

A New York City-based not-for-profit devoted to advancing innovative health care initiatives.

Read More
Portfolio Companies

Deerfield generally maintains a combined portfolio of more than 150 private and public investments across the life science, medical device, diagnostic, digital health and health service industries at all stages of evolution from start-up to mature company.

Read More View Portfolio Companies
Research Collaborations

Deerfield partners with leading academic research centers, providing critical funding and expertise to further sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.

Read More View Research Collaborations
Strategic Partners

As a strategic partner, Deerfield offers capital, scientific expertise, business operating support, and unique access to innovation.

Read More
Deerfield Foundation

The Deerfield Foundation is a New York City-based not-for-profit organization whose mission is to improve health, accelerate innovation and promote human equity.

Read More Meet the Foundation Team
Cure Campus

Cure is a 12-story innovations campus in New York City that intends to bring together innovators from academia, government, industry, and the not-for-profit sectors to advance human health and accelerate the fight against disease.

Read More Join the Cure Email List
Cure Programming

Cure has a series of expert lectures intended to advance thought in healthcare, management, innovation, policy, and other relevant subjects. This fosters growth and education for those at Cure and its guests.

Events at the Cure

Deerfield Leads $34 Million Investment in Lumos Pharma

New York, NY – April 6, 2016- Deerfield Management Company leads a $34 million investment in Lumos Pharma’s Series B financing. The proceeds of the financing will be used to develop LUM-001, Lumos’ lead compound, for the treatment of Creatine Transporter Deficiency (CTD). Funding will also be used to further develop other therapeutics in the company’s pipeline. 

Creatine Transporter Deficiency is a rare defect which causes patients, mostly young boys, to be unable to actively transport creatine across the blood-brain barrier, resulting in delays inexpressive speech and mental development, and also causes these boys to experience behavioral abnormalities, epilepsy and seizures. Due to the clinical presentation, those afflicted with CTD are often misdiagnosed with autism.  This disease is severely debilitating,and the young boys require lifelong care. CTD is the second leading cause of X-linked mental retardation in males after Fragile X Syndrome. LUM-001 is a disease modifying therapy and may significantly alter the development of the defect and symptoms.

“We are proud to be partnering with a pioneer in the orphan disease space to develop a cure for CTD. With the similarities of symptoms with autism often leading to misdiagnosis, and the lack of a current effective therapy, CTD often goes untreated. We believe Lumos has the cutting edge science and technology needed to develop LUM-001 to be the first treatment to help these young boys,” stated Cameron Wheeler, a Principal from Deerfield. 

“We are excited to have Deerfield as a partner in Lumos. We believe Deerfield has the balance, flexibility and skills to help guide us as we move this important cure forward. Deerfield has a strong history in the orphan space and is committed to improving the lives of patients with CTD,” stated Rick Hawkins, CEO of Lumos Pharma.

About Lumos

Lumos Pharma is focused on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. Lumos Pharma is led by an experienced management team withlongstanding experience in the rare disease space. Lumos Pharma’s lead compound is supported by the National Institutes of Health’s Therapeutics for Rare and Neglected Diseases (TRND) program. 

About Deerfield

Deerfield is an investment management firm committed to advancing healthcare through investment, information and philanthropy.

For more information, please visit


Deerfield Management Company
Karen Heidelberger, 212-692-7140
[email protected]